COVID-19 antiviral treatments: Guidelines and resources
SA Health Clinical Guidelines
Treatment Recommendations for Hospitalised Adult Patients
The Treatment Recommendations for Hospitalised Adult Patients clinical guideline has been developed by the Central Adelaide Local Health Network Antimicrobial Stewardship Committee and endorsed for use statewide in SA Health by the COVID-19 Medicines Advisory Group. For the latest updates to PBS eligibility, please check the PBS website.
Medication Management of Mild Illness in the Outpatient Setting
The following COVID-19 Mild Illness treatment guidelines have been developed by the Central Adelaide Local Health Network Antimicrobial Stewardship Committee and initially endorsed for SA Health use by the South Australia Medicines Advisory Committee on 19 January 2022, the guidelines have been updated to reflect changes in clinical evidence, national and international guidelines, and patient access pathways such as updates to the Pharmaceutical Benefits Scheme (PBS).
For the latest updates to PBS eligibility,
please check the PBS website.
- COVID-19 Medication Management of Mild Illness in the Outpatient Setting Clinical Guideline (PDF 1574KB)
- Risk factors for severe COVID-19 and classification of immunosuppressed patients (PDF 215KB)
- Classification of disease severity
-
Drug interaction checker
Prescriber information sheets
- Nirmatrelvir-Ritonavir (Paxlovid®) (PDF 257KB)
- Molnupiravir (Lagevrio®) (PDF 557KB)
- Fact Sheet: Clozapine and antiviral treatments for mild COVID-19 (PDF 126KB)
- Nirmatrelvir plus ritonavir (Paxlovid®) Product
Information
- Molnupiravir (Lagevrio®) Product Information
- Remdesivir (Veklury®) Product Information
- Nirmatrelvir-ritonavir (Paxlovid®) for people receiving dialysis treatment - Fact Sheet (PDF 459KB)
Drug monographs
- Nirmatrelvir plus ritonavir (Paxlovid®) monograph (PDF 542KB)
- Molnupiravir (Lagevrio®) monograph (PDF 457KB)
- Remdesivir (Veklury®) monograph (PDF 548KB)
Australian guidelines and recommendations
Medication recommendations for COVID-19 can change rapidly due to demand and supply constraints, ongoing research and as novel agents are discovered. For the most up to date Australian guidelines and recommendations refer to:
- National COVID-19 Clinical Evidence Taskforce (The Australian Living Guidelines)
- COVID-19 Resources: NSW Therapeutic Advisory Group
- Clinical Excellence Commission: Medication Safety Updates
- ATAGI clinical guidance for COVID-19 vaccine providers for clinical recommendations for COVID-19 vaccines, and information on vaccination status.
Patient education resources
molnupiravir (Lagevrio®)
- Molnupiravir (Lagevrio) Patient Information (PDF 207KB)
- Lagevrio Consumer Medicines Information (CMI)
nirmatrelvir plus ritonavir (Paxlovid®)
- Nirmatrelvir plus Ritonavir (Paxlovid) Patient Information (PDF 306KB)
- COVID-19 Treatment for people receiving dialysis: nirmatrelvir-ritonavir (Paxlovid®) - Fact sheet (PDF 282KB)
- Paxlovid Consumer Medicines Information (CMI)